NNC0268-0965

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2 New Dexcom G7 automated insulin delivery integrations* further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7 app updates, including Direct to Apple Watch,† demonstrate relentless commitment to innovation and improving user experience. SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando. Dexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s This year at ADA, Dexcom is presenting more data on Dexcom CGM use among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin.3-5 Additionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s.1 As the use of GLP-1s continues to grow, data continues to show people with Type 2 diabetes on GLP-1s are more likely to use CGM after starting the medication.2 Going beyond Type 2 diabetes, another study presented at ADA demonstrates Dexcom CGM is a valuable behavior modification tool for people with prediabetes.6 In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider interactions. “As the evidence of the benefits of CGM use by people with Type 2 diabetes and prediabetes continues to grow, Dexcom is uniquely positioned to address their needs through our portfolio of products,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Dexcom G7 is the most accurate and affordable7 CGM system available for people with Type 1 diabetes and Type 2 diabetes who use insulin, and when Stelo by Dexcom launches in late August, we will have a glucose biosensor available for purchase without a prescription designed specifically for people with Type 2 diabetes not using insulin.” Dexcom: The clear choice for automated insulin delivery Dexcom further solidified its position as the industry leader in connectivity this morning with Insulet’s announcement commencing the launch of the Omnipod 5 with Dexcom G7. Beginning today, new Omnipod 5 users can experience the benefits of the only tubeless AID system connected to Dexcom G7, the most accurate CGM7 powering AID systems. Dexcom G7 will be available for existing Omnipod 5 users in the U.S. later this year. Dexcom CGM currently connects to more AID pump options than any other CGM brand in the U.S.; the iLet Bionic Pancreas insulin pump, the Tandem pump portfolio (Tandem Mobi and t:slim X2 insulin pumps), and now Omnipod 5. For those seeking more information about the recent integration of Dexcom G7 and the Tandem Mobi insulin pump, there will be an evening education event during ADA on June 22, 2024, from 6-8 p.m. Registration is open to U.S. healthcare provider attendees. With hundreds of thousands of users now connected to insulin pumps, pens and digital health apps, Dexcom is the undisputed leader in CGM connectivity. Dexcom: A relentless commitment to innovation and customer experience For 25 years, Dexcom has been the pioneer in continuous glucose monitoring, continually innovating on behalf of people with diabetes. The release of new app updates this month has further improved the features and user experience of Dexcom G7, the world’s most accurate CGM system.7 Dexcom G7 is now the first and only CGM with Direct to Apple Watch connectivity, allowing users to leave their iPhone ‡ behind and manage diabetes hands-free.​ It’s now the first and only CGM with automated activity and medication logging, helping users visualize how activity and medications affect glucose in real-time. And with enhanced Bluetooth with Rapid Reconnect, Dexcom G7 now has 65% farther §,8 Bluetooth range and quicker reconnection when signal is lost, keeping users connected longer.​ For a detailed overview of all the Dexcom CGM symposia and presentations at ADA this year, visit the Dexcom Clinical Education Resources Microsite. About DexCom, Inc. DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers and providers, Dexcom works to simplify and improve diabetes management around the world. For more information on Dexcom, visit . Category: IR * To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/integrate. † Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. ‡ Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 20 feet of the Dexcom G7. § Dexcom G7 now has a 33 ft Bluetooth range, 13 feet farther than the previous 20 ft range. 1 Nemlekar P, Hannah K, Norman GJ. The Combined Effect of CGM with Antidiabetes Medications and the Association with Improved A1C in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy (NIT). Poster presentation 1914-LB. 2 Wang A, Xu Y, Norman GJ, Reid JL, Singh H, Yang L. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1 RA Therapy – Real-World Data. Poster presentation 1922-LB. 3 Grace T, Layne JE, Hicks C, Green CR, Walker TC. The Dexcom Community Glucose Monitoring Project for People with Type 2 Diabetes – One Year Outcomes. Poster presentation 982-P. 4 Layne JE, Jepson LH, Carite A. Bergenstal RM, Long-term Improvement in CGM-Measured Glycemic Control in Adults with Type 2 Diabetes Not Treated with Insulin. Poster presentation 983-P. 5 Norman GJ, Fernandes J, Nemlekar P, Lupton L, Berk A. A1c Change After Initiating Continuous Glucose Monitoring (CGM) For People with Diabetes in a Large US Managed Health Care Plan. Oral presentation 143-OR. 6 Crawford MA, Hicks C, Zhou T, Xu Y, Singh H, Chernavvasky DR, Levister C, Shah N, Rouviere M, Tamru A, Kaplan L, Lam DW, O’Malley G, Levy, CL. Value of Dexcom CGM for Therapy Optimization and Glycemic Outcomes in Post-Hospital Discharge T2D Patients: An Exploratory Study. Poster presentation 1133-P. 7 Dexcom, data on file, 2024. 8 Dexcom G7 CGM System User Guide. 2023. View source version on businesswire.com: Contacts Source: DexCom, Inc. View this news release online at:

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both of the leading CGM sensor brands, Dexcom and Abbott FreeStyle Libre. “Expanding global access to Omnipod 5 is one of our top priorities. With the exciting, updated compatibility with both the Abbott FreeStyle Libre 2 Plus and the Dexcom G6 sensors, thousands more people with diabetes can enjoy the incredible freedom of tubeless, automated insulin delivery without having to change their CGM sensor brand. This is a game-changer for diabetes management,” said Patrick Crannell, Insulet Senior Vice President and International General Manager. Omnipod 5 is the first tubeless, waterproof1 AID system with proactive glucose control. The System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia.2,3 “Pod therapy is great because it is tubeless, and easy to use,” said Dion Screever, an 18-year-old student from the Netherlands. “When I started on Omnipod 5, I immediately noticed that my blood sugar was in range with much less effort from me, because of the automated insulin delivery technology. As someone who has lived with type 1 diabetes for nine years, Omnipod 5 has been life changing, giving me more freedom to live the way I want to.” Multiple sensor integrations including Dexcom G6 and Abbott FreeStyle Libre 2 Plus give prescribers greater flexibility when recommending a sensor for their patients and make it simple to begin AID therapy with Omnipod 5. Customers can select the sensor they would like to connect to Omnipod 5 during the setup process. Professor Partha S. Kar, Type 1 Diabetes and Technology Lead at NHS England and a consultant endocrinologist at Portsmouth Hospitals NHS Trust said, “The recent integration of Omnipod 5 with the FreeStyle Libre 2 Plus sensor will allow the life changing benefits of AID to be brought to many more people throughout the U.K., and also in the Netherlands. This is an exciting next step on this incredible journey to simplify life for people with type 1 diabetes.” To learn more or to get started, visit the Omnipod website. 1 The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod® 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed. The FreeStyle Libre 2 Plus sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes. 2 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. 3 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com. ©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. View source version on businesswire.com: Contacts Investor Relations: Deborah R. Gordon Vice President, Investor Relations (978) 600-7717 dgordon@insulet.com Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 awiczek@insulet.com Source: Insulet Corporation View this news release online at: